Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Novel therapies in the treatment of bladder cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.19
Views: 2723

Dr Petros Grivas and Dr Andrea Necchi

Dr Petros Grivas (Seattle Cancer Care Alliance, Seattle, USA) and Dr Andrea Necchi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) discuss novel treatment strategies and the latest updates from ASCO 2019 for bladder cancer. 

The experts discuss ongoing trials in non-muscle invasive bladder cancer before discussing recent advancements in muscle invasive disease including the potential of neo-adjuvant immunotherapy.

The discussion goes on to cover the potential of antibody drug conjugates for the treatment of patients with metastatic bladder cancer, with the experts commenting on how these therapies may result in a treatment option for unselected patients groups.

Dr Necchi and Dr Grivas conclude the session by discussing the variation in treatment options and genomic testing between different countries, identifying the need for different stakeholders to join the conversation on how best to manage patients with metastatic disease.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company). 

Current clinical trials in non-muscle invasive bladder cancer
Multidisciplinary management of bladder cancer patients
PURE 01 trial evaluating pembrolizumab as a neoadjuvant therapy
Antibody drug conjugates (ADCs) as a treatment for metastatic bladder cancer
Potential application of ADCs as a neoadjuvant therapy and in combination with immunotherapy
Improving access to therapy and cancer care
Genomic sequencing for bladder cancer patients

Immuno-Oncology: Advances in Cancer Treatment e-learning course

Take our free e-learning course on the latest developments in immunotherapy here: http://bit.ly/ecancerimmunotherapy

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation